In Nov. 2022, the U.S. nonprofit Multidisciplinary Association for Psychedelic experiments (MAPS) announced that it experienced concluded a second phase-three trial on MDMA like a treatment method for PTSD—a move https://louisebcoa174115.blogoscience.com/profile